NDA 211230 · Axsome Malta
Sunosi
Solriamfetol Hydrochloride · Oral · Dopamine and Norepinephrine Reuptake Inhibitor
NovelOrphanLast checked: Nov 20, 2026Latest source record: Jun 28, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2019
Mar 20, 2019
Approved uses
2
Original approval plus efficacy supplements
Registered trials
31
15 Phase 3, 8 recruiting
FAERS reports
3,852
1,607 serious, 14 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect May 5, 2026.
SUNOSI is indicated to improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (OSA) [see Clinical Studies ( 14 )] . Limitations of Use SUNOSI is not indicated to treat the underlying airway obstruction in OSA. Ensure that the underlying airway obstruction is treated (e.g., with continuous positive airway pressure (CPAP)) for at least one month prior to initiating SUNOSI for excessive daytime sleepiness. Modalities to treat the underlying airway obstruction should be continued during treatment with SUNOSI. SUNOSI is not a substitute for these modalities. SUNOSI is a dopamine and norepinephrine reuptake inhibitor (DNRI) indicated to improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (OSA). ( 1 ) Limitations of Use SUNOSI is not indicated to treat the underlying airway obstruction in OSA. Ensure that the underlying airway obstruction is treated (e.g., with continuous positive airway pressure (CPAP)) for at least one month prior to initiating SUNOSI for excessive daytime sleepiness. Modalities to treat the underlying airway obstruction should be continued during treatment with SUNOSI. SUNOSI is not a substitute for these modalities. ( 1 )
Mechanism: The mechanism of action of solriamfetol to improve wakefulness in patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea is unclear. However, its efficacy could be mediated through its activity as a dopamine and norepinephrine reuptake inhibitor (DNRI).
Therapeutic areas: Kidney and urology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 20, 2019 Original approval · Type 1 - New Molecular Entity NovelOrphanLabelLetterReview
- Mar 20, 2019 Original approval · Efficacy NovelLabelLetterReview
2 products under this application
- SUNOSI · SOLRIAMFETOL HYDROCHLORIDE EQ 75MG BASE · TABLET, ORAL · Prescription · TE AB
- SUNOSI · SOLRIAMFETOL HYDROCHLORIDE EQ 150MG BASE · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Solriamfetol" as an intervention, any sponsor and status, largest first.
- RECOVER-SLEEP: Platform ProtocolPivotal-lookingCompleted
Duke UniversityAcademic, hospital or other
NCT06404086 · 830 participants · Start Jul 31, 2024 · Primary completion Dec 31, 2025
Drug: Modafinil; Modafinil Placebo and 4 more · For: Long COVID; Long COVID-19; Hypersomnia and 1 more
Sites: Phoenix, Arizona; Tucson, Arizona; Palo Alto, California · 47 sites in all
- "A Long-Term Safety Study of JZP-110 in the Treatment of Excessive Sleepiness in Subjects With Narcolepsy or OSA"Pivotal-lookingCompleted
Jazz PharmaceuticalsJazz Pharmaceuticals (JAZZ)
NCT02348632 · 645 participants · Start May 2015 · Primary completion Dec 2017
Drug: JZP-110 · For: Narcolepsy; Obstructive Sleep Apnea
Sites: Birmingham, Alabama; Glendale, Arizona; Scottsdale, Arizona · 80 sites in all
- Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SUSTAIN)Pivotal-lookingRecruiting
Axsome Therapeutics, Inc.Industry
NCT06568367 · 520 participants (planned) · Start Aug 1, 2024 · Primary completion Dec 2026
Drug: Solriamfetol 150 mg; Solriamfetol 300 mg and 1 more · For: Excessive Sleepiness; Shift-work Disorder
Sites: Auburn, Alabama; Cullman, Alabama; Chandler, Arizona · 49 sites in all
- A Study to Assess the Efficacy and Safety of Solriamfetol in Subjects With ADHD (FOCUS)Pivotal-lookingCompleted
Axsome Therapeutics, Inc.Industry
NCT05972044 · 516 participants · Start Jul 6, 2023 · Primary completion Feb 7, 2025
Drug: Solriamfetol 150 mg; Solriamfetol 300 mg and 1 more · For: ADHD
Sites: Encino, California; Garden Grove, California; Newport Beach, California · 42 sites in all
- Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using SolriamfetolPivotal-lookingRecruiting
Axsome Therapeutics, Inc.Industry
NCT07484217 · 508 participants (planned) · Start Feb 23, 2026 · Primary completion Dec 2028
Drug: Solriamfetol 150 MG; Placebo · For: Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms
Sites: Tucson, Arizona; Bellflower, California; Chino, California · 40 sites in all
- "Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in OSA"Pivotal-lookingCompleted
Jazz PharmaceuticalsJazz Pharmaceuticals (JAZZ)
NCT02348606 · 476 participants · Start May 2015 · Primary completion Dec 2016
Drug: JZP-110; Placebo oral tablet · For: Obstructive Sleep Apnea
Sites: Glendale, Arizona; Scottsdale, Arizona; Little Rock, Arkansas · 59 sites in all
- Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-3)Pivotal-lookingRecruiting
Axsome Therapeutics, Inc.Industry
NCT07717892 · 468 participants (planned) · Start Jun 25, 2026 · Primary completion Jun 30, 2028
Drug: Solriamfetol Dose A; Solriamfetol Dose B and 1 more · For: ADHD
Sites: Dothan, Alabama; Little Rock, Arkansas; Anaheim, California · 31 sites in all
- Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-2)Pivotal-lookingRecruiting
Axsome Therapeutics, Inc.Industry
NCT07717879 · 468 participants (planned) · Start Jul 6, 2026 · Primary completion Jun 30, 2028
Drug: Solriamfetol Dose A; Solriamfetol Dose B and 1 more · For: ADHD
Sites: Dothan, Alabama; Little Rock, Arkansas; Anaheim, California · 32 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective541
- anxiety343
- headache320
- nausea307
- fatigue275
- product administration interrupted272
- somnolence255
- off label use253
- product dose omission issue201
- surgery180
- dizziness173
- depression168
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2015 | 7 |
| 2016 | 23 |
| 2017 | 20 |
| 2018 | 9 |
| 2019 | 105 |
| 2020 | 535 |
| 2021 | 532 |
| 2022 | 800 |
| 2023 | 564 |
| 2024 | 599 |
| 2025 | 429 |
| 2026 | 229 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Sunosi (Solriamfetol HCl)
2024 spending
$21.0M
Beneficiaries
4,007
20,031 claims
Per beneficiary
$5,247
$28.56 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $4,965,429 |
| 2021 | $10,241,349 |
| 2022 | $13,749,335 |
| 2023 | $17,479,999 |
| 2024 | $21,025,661 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine clinical practice guideline.
Maski K, Trotti LM, Kotagal S, et al. · J Clin Sleep Med 2021 · Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine systematic review, meta-analysis, and GRADE assessment.
Maski K, Trotti LM, Kotagal S, et al. · J Clin Sleep Med 2021 · Meta-Analysis, Research Support, N.I.H., Extramural
- Effects of solriamfetol on on-the-road driving performance in participants with excessive daytime sleepiness associated with obstructive sleep apnoea.
Vinckenbosch F, Asin J, de Vries N, et al. · Hum Psychopharmacol 2022 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Solriamfetol for Excessive Sleepiness in Early-Morning Shift Work Disorder.
Zitting KM, Gilmore KR, Lockyer BJ, et al. · NEJM Evid 2026 · Randomized Controlled Trial
- Efficacy and safety of solriamfetol for excessive daytime sleepiness in narcolepsy and obstructive sleep apnea: a systematic review and meta-analysis of clinical trials.
Subedi R, Singh R, Thakur RK, et al. · Sleep Med 2020 · Meta-Analysis, Systematic Review
- Effects of solriamfetol on on-the-road driving in participants with narcolepsy: A randomised crossover trial.
Vinckenbosch F, Lammers GJ, Overeem S, et al. · Hum Psychopharmacol 2023 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
Sponsor: Axsome Malta
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.